19819-18-2

Basic information

• Product Name: 2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
• Synonyms: [1]benzothieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-
• CAS NO: 19819-18-2
• Molecular Formula: C₁₆H₁₄N₂OS
• Molecular Weight: 282.3602
• Mol File: 19819-18-2.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 409.5°C at 760 mmHg
• Flash Point: 201.5°C
• Density: 1.43g/cm³
• Vapor Pressure: 2.72E-07mmHg at 25°C
• Refractive Index: 1.755
• CAS DataBase Reference: 2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one(19819-18-2)
• EPA Substance Registry System: 2-phenyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one(19819-18-2)

Safety Data

• Hazardous Substances Data: 19819-18-2(Hazardous Substances Data)

Upstream product

• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 100-47-0 benzonitrile 
• 4815-28-5 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 
• 98-88-4 benzoyl chloride 
• 825-60-5 benzimidic acid ethyl ester 
• 5936-58-3 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid 
• 73696-35-2 5,6,7,8-tetrahydro-2-phenyl-4H-benzo<4,5->thieno<2,3-d><3,1>-oxazin-4-one 
• 52535-73-6 4,5,6,7-tetrahydrobenzothiophene-2-benzoylamino-3-carboxylic acid 
• 108-94-1 cyclohexanone 
• 100-52-7 benzaldehyde 
• 93-89-0 benzoic acid ethyl ester 
• 19819-17-1 2-benzamido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 

Downstream Products

• 1225504-81-3 2-phenyl-4-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine 
• 1225504-83-5 2-phenyl-3-prop-2-yn-1-yl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one 
• 60557-11-1 N,2-diphenyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine 
• 60557-12-2 ethyl-phenyl-(2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine 
• 60557-14-4 4-(4-methyl-piperazin-1-yl)-2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine 
• 60557-10-0 dibutyl-(2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine 
• 60557-13-3 4-morpholino-2-phenyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
• 35149-35-0 4-methanesulfinylmethyl-2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine 
• 35149-33-8 2,4-diphenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine 
• 35149-36-1 2-phenyl-4-methoxy-5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidine 
• 60557-08-6 methyl-(2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine 
• 60557-09-7 dimethyl-(2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine 
• 35149-34-9 4-methyl-2-phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine 
• 83548-65-6 (2-Phenyl-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazine 

Relevant articles and documents

Design, synthesis, and biological evaluation of new thieno[2,3-d] pyrimidine derivatives as targeted therapy for PI3K with molecular modelling study

Cancer is one of the most aggressive diseases characterised by abnormal growth and uncontrolled cell division. PI3K is a lipid kinase involved in cancer progression which makes it fruitful target for cancer control. 28 new morpholine based thieno[2,3-d] p

ZnO-CeO2 nanocomposite: Efficient catalyst for the preparation of thieno[2,3-d]pyrimidin-4(3H)-one derivatives

The Zinc oxide-cerium oxide (ZnO-CeO2) nanocomposite was prepared by a coprecipitation method and characterized by X-ray diffraction (XRD), field emission scanning electron microscopy (FE-SEM), and particle size distribution analysis. The XRD p

Design, synthesis, and biological activity of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as anti-inflammatory agents

We designed and synthesized 26 prototype compounds and studied their anti-inflammatory activity and underlying molecular mechanisms. The inhibitory effects of the compounds on the production of nitric oxide (NO), cytokines, inflammatory-related proteins, and mRNAs in lipopolysaccharide (LPS)-stimulated macrophages were determined by the Griess assay, Enzyme linked immunosorbent assay (ELISA), Western blot analysis, and Reverse transcription-Polymerase Chain Reaction (RT-PCR), respectively. Our results indicated that treatment with A2, A6 and B7 significantly inhibited the secretion of NO and inflammatory cytokines in RAW264.7 cells without demonstrable cytotoxicity. It was also found that A2, A6 and B7 strongly suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase enzyme COX-2, and prevented nuclear translocation of nuclear factor κB (NF-κB) p65 by inhibiting the degradation of p50 and IκBα. Furthermore, the phosphorylation of mitogen-activated protein kinase (MAPKs) in LPS-stimulated RAW264.7 cells was significantly inhibited by A2, A6 and B7. These findings suggest that A2, A6 and B7 may operate as an effective anti-inflammatory agent through inhibiting the activation of NF-κB and MAPK signaling pathways in macrophages. Moreover, rat paw swelling experiments showed that these compounds possess anti-inflammatory activity in vivo, with compound A6 exhibiting similar activities to the reference drug Indomethacin.